Active Pharmaceutical Ingredients
- Industrial Coatings
- Dyes and Pigments
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
- Analytical Chemistry
- Cosmetic Ingredient
- Pharmaceutical Intermediates
Author: Tian Qing
Event: On the evening of Wednesday, August 18th, Beijing time, the Hong Kong-listed company China Biopharmaceuticals announced its performance forecast.
Kexing Zhongwei is one of the wholly-owned subsidiaries of Kexing Holding Biotechnology Co.
The domestic epidemic began to break out in a scattered manner in the second quarter.
In December last year, China Biopharmaceuticals invested US$515 million in the shares of Kexing Zhongwei, holding 15.
During the interim report period, China Biopharma's profit was also affected by the beautiful sales of Coxing Zhongwei vaccines, and the profit contribution accounted for more than the main business
Conclusion: At present, there are 5 foreign brands in the WHO emergency use list of new crown vaccines, and another 2 domestic new crown vaccines are Beijing Biotech and Kexing Zhongwei.